Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO and the shorts continue | Sirpeter | investorshub | 09/18/2023 5:06:25 PM |
$OKYO The gaining | Pisd | investorshub | 09/18/2023 5:01:29 PM |
Have a look at this | Count Crypto | investorshub | 09/18/2023 4:47:15 PM |
Price trading | mfayman | investorshub | 09/18/2023 4:39:32 PM |
The now up | Sirpeter | investorshub | 09/18/2023 3:49:25 PM |
$OKYO MomentumIts gaining last up | mfayman | investorshub | 09/18/2023 3:37:01 PM |
MomentumIts trading up | Sirpeter | investorshub | 09/18/2023 3:27:42 PM |
Good news recently, we should start to see this one move | StocksNcash | investorshub | 09/18/2023 1:39:14 PM |
Time for a bounce? | Boris the Spider | investorshub | 09/18/2023 10:35:29 AM |
and the shorts continue | glenn1919 | investorshub | 09/18/2023 10:18:52 AM |
$OKYO Looks pretty positive | mfayman | investorshub | 09/18/2023 7:34:30 AM |
$OKYO bulls and bears | mfayman | investorshub | 09/18/2023 7:21:17 AM |
Price now | mfayman | investorshub | 09/18/2023 5:19:30 AM |
Price trading | Sirpeter | investorshub | 09/18/2023 3:59:22 AM |
MomentumIts gaining last up | Pisd | investorshub | 09/17/2023 11:05:45 PM |
$OKYO MomentumIts now last trade up | mfayman | investorshub | 09/17/2023 10:35:34 PM |
$OKYO Good news recently, we should start to see this one move | mfayman | investorshub | 09/17/2023 8:30:47 PM |
$OKYO The now | mfayman | investorshub | 09/17/2023 8:13:53 PM |
Long and strong lets hope im right | Count Crypto | investorshub | 09/17/2023 4:57:09 PM |
$OKYO great news | Pisd | investorshub | 09/17/2023 3:45:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...